{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-24-000027","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.206705+00:00","generated_at":"2026-06-03T01:57:09.325841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M","bullets":["Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.","Net income $306.6M ($6.17 diluted EPS) vs $240.9M ($4.86 EPS) in Q1 2023.","Implemented $1B accelerated share repurchase with Citi; initial delivery of 3.275M shares.","Tyvaso DPI sales $227.5M (+92% YoY); nebulized Tyvaso $145.0M (+21%).","Revenue growth driven by increased patient utilization and Part D redesign tailwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-24-000027","json":"https://secwatch.observer/filing/0001082554-24-000027.json","markdown":"https://secwatch.observer/filing/0001082554-24-000027.md","text":"https://secwatch.observer/filing/0001082554-24-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000027/0001082554-24-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000027/uthr-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:57:09.325841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}